Millennium Management
FULC icon

Millennium Management’s Fulcrum Therapeutics FULC Stock Holding History

Millennium Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,000
Closed -$828K – 7136
2022
Q1 		$828K Buy
+35,000
New +$495K ﹤0.01% 4714

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management's FULC Position: Q1 2026 in Review

Millennium Management increased its Fulcrum Therapeutics (FULC) stake by 555% in Q1 2026, buying an estimated $2.8M and bringing the position to 356,471 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3562.

Millennium Management first reported a position in FULC in Q3 2019 and has held it in 23 quarters since. The position peaked at $8.47M in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Millennium Management held 356,471 shares of Fulcrum Therapeutics worth $2.73M as of Q1 2026.
  • Millennium Management bought 302,040 Fulcrum Therapeutics shares in Q1 2026, an estimated $2.8M.
  • Fulcrum Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3562 holding.
  • Millennium Management first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • Millennium Management's Fulcrum Therapeutics position peaked at $8.47M in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.